Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Xipiro Pharmaceuticals
Huntington, West Virginia, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
Xipiro Pharmaceuticals is a preclinical-stage biotechnology startup focused on developing peptide-based therapeutics to treat oxidative stress-related diseases. Founded by researchers from Marshall University, the company is developing its lead candidate, pNaKtide, a cell-permeable peptide derived from the Na-K-ATPase alpha-1 subunit. pNaKtide acts as a specific inhibitor of the Na-K-ATPase/c-Src signaling pathway, blocking the feed-forward oxidant amplification loop. Xipiro is advancing pNaKtide for the treatment of neovascularization disorders of the eye, anemia of chronic kidney disease (CKD), and uremic cardiomyopathy.
- Therapeutic areas
- NephrologyOphthalmologyCardiovascular
- Modalities
- PeptidesBiologic
- Industry
- Biotech
02
Partnerships
Marshall University
Beyond the preview
Go deeper on Xipiro Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Xipiro Pharmaceuticals.